Pleocytosis and Elevation of Prostaglandins
SUMMARY A marked pleocytosis and increase in the levels of prostaglandin F* (PGF U ) and prostaglandin E, (PGE,) were noted in cerebrospinal fluid of dogs within two hours following the intracisternal injection of thrombin. Quantitation of the prostaglandins (PCs) was done by gas chromatography-mass spectroscopy using deuterated PGF,. and PGE, as internal standards. Whereas the levels of these prostaglandins were below the sensitivity of the method in control animals, a marked increase was noted following thrombin. PGF ta levels were 15-21 ng/ml and the PGE, levels were 55-72 ng/ml. This concentration of the PC's is adequate to cause spasm of the cerebral vessels and could explain the spasm which occurs following the intracisternal injection of thrombin. These two effects, a pleocytosis and elevation of PG levels, may be specific to thrombin.
A NUMBER OF STUDIES indicate that the genesis of cerebral vasospasm is complex. Many substances derived from brain tissue 1 ' * or from blood 8 " 8 produce cerebral vasospasm experimentally. The fact that thrombin" is among these seems of special interest because of its use in neurosurgery.
The spasm generated by thrombin is delayed in onset, suggesting that thrombin might be acting indirectly, possibly by stimulating the synthesis and/or release of some spasmogen." The present study was undertaken to elucidate the mechanism(s) by which thrombin might induce cerebrovascular spasm.
The results clearly show that two hours following the intrathecal injection of thrombin there is a marked pleocytosis suggesting an inflammatory response as well as a significant increase in the concentrations of prostaglandins F, a (PGF ta ) and Ej (PGE 2 ) in cerebrospinal fluid (CSF).
These findings are of special significance because inflammation and cerebral vasospasm are clinical observations in patients with subarachnoid hemorrhage (SAH). Both PGF 2a and PGE2 are spasmogenic on cerebral vessels'-' and may be involved in the inflammatory process.*''
Materials and Methods
Animals -Mongrel dogs of both sexes weighing from 16-31 kg were anesthetized with pentobarbital sodium (30 mg/kg) intravenously.
Thrombin Injection and Collection of CSF -In the animals treated with thrombin four ml of CSF were removed from the cisterna magna via an 18 ga. spinal needle. One-half ml of the CSF was taken for cell counts and the remainder was mixed with 1,000 units of Thrombin N. F. With the needle left in place the CSF containing the thrombin was reinjected into the cisterna magna and the spinal needle removed. At the end of two hours a second cisternal puncture was made and 10-19 ml of CSF withdrawn. The first and last 0.5 ml fraction collected was taken for cell counts. The remainder was added to glass tubes containing 1.9 mg EDTA and stored at -40° C until analyzed for PGEj and PGF 2a .
Saline, PGE, or Air Injection -The procedure used was similar to that described above except that 0.5-1.0 ml of CSF was replaced with an equal volume of either 0.9% saline, 5.0% saline or 7.2 ^g PGEj dissolved in 1.0 ml of saline. In the dogs receiving an air embolus a total of 5 ml air was injected.
Extraction of Prostaglandins -Deuterated PGF, a and PGE 2 were added to all samples of CSF and the pH adjusted to 9.0 with IN NaOH. The samples were initially extracted with hexane, 10 ml X 2, discarding the hexane. After adjusting the samples to pH 3.5 with IN HC1, extraction was carried out with chloroform, 10 ml X 3. The chloroform was evaporated to dryness and the samples were methylated with a diethyl ether-diazomethane solution. 8 Further purification was accomplished with a silicic acid column. A solution of the methylated derivative in benzene/ethyl acetate (9:1) was placed on the column and nonpolar contaminants were eluted with 25 ml benzene/ethyl acetate (9:1). The prostaglandins were then eluted from the column with 25 ml ethyl acetate/methanol (9:1). Prior to quantitation the samples were dried and treated with a solution of benzene/piperidine/N-trimethylsilylimidazole (TSIM) (1:1:1). Under these conditions the PGF, a -ME is converted into the corresponding tris-TMS derivative while PGE 2 -ME is converted into mono-TMS derivative of prostaglandin B 2 -ME. 9 Quantitation of Prostaglandins -The prostaglandins were quantitated by selected ion monitoring (SIM) using an LKB-9000 gas chromatograph/mass spectrometer which was interfaced to a PDP-8/E computer for data acquisition and reduction. 10 Deuterated PGF 2a and PGE, were used as the internal standards and carrier for these analyses.
The prostaglandin derivatives were separated by gas chromatography on 3% OV-210 (6' X 3 mm glass coiled column) at 215° C. The retention time for the mixture of PGFto and deuterated PGF 2a was approximately 3 minutes. The PGB 2 derivatives derived from PGE 2 and deuterated PGE 2 had a retention time of approximately 9 minutes.
The computer automatically maintained optimal accelerating voltage during analyses, so the intensities of m/e 423 and 427, representing the protium and deuteriumlabeled species of PGF 2a respectively, and intensities for PLEOCYTOSIS, PROSTAGLANDINS IN CSF AFTER THROMB1W/Hagen el at. •N PGB, at m/e 420 and 424, representing the protium and deuterium labeled species of PGE,, respectively, were always focused to maximum sensitivity. Areas of the peak, as well as peak heights, for each ion were computer integrated, a standard curve was determined with reference samples of known quantity, and the prostaglandins were quantified using an internal standard.
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Results
Two hours following the intracisternal injection of 1,000 units thrombin, the levels of PGF, a and PGE, in CSF were markedly elevated (table 1) . PGF, a rose from non-detectable levels (< 0.1 ng/ml) in control animals to levels of 15-21 ng/ml in thrombin treated animals. PGE 2 likewise showed a marked increase rising from non-detectable levels (< 0.5 ng/ml) to levels of 55-72 ng/ml, approximately three times higher than PGF 2a .
In addition to the increase in prostaglandins, a marked pleocytosis was noted in dogs treated with thrombin (table  2) . Prior to the treatment with thrombin the cell counts were in the normal range" but there was a significant increase in cells after thrombin and a change in cell type with polymorphonuclear cells becoming more prominent.
When assayed for prostaglandins, only CSF from thrombin treated animals had elevated levels. Thus the action of thrombin is somewhat specific since no other treatment, including a bolus injection of PGE, or air, caused a pleocytosis.
Discussion
Thrombin, when present in cerebral spinal fluid, is capable of initiating two effects: a marked pleocytosis suggesting an inflammatory response and an elevation in the levels of PGFjg and PGE,. These two observations are believed to be related.
Thrombin may be acting on cerebral tissues in a manner similar to an irritant leading to inflammation and subsequent release of PG's. Since prostaglandins are known to be released during inflammation"- 7 and by polymorphonuclear leucocytes, 11 ' u it is possible that the increased levels were the result of this process. Such an indirect effect would explain he delay in onset of spasm that one sees following thrombin n contrast to the prompt spasm induced by PG's injected inrathecally. 8 Thrombin has been demonstrated to cause ievere endothelial injury to isolated strips of rabbit aorta ivith marked histological changes noted after 15 minutes of sxposure." Similar changes could potentially occur in ;erebral vessels.
It is also possible that thrombin is directly stimulating the synthesis of PGF, a and PGE, by brain tissue or cerebral vessels since brain tissue has been shown to synthesize these two prostaglandins" as has bovine mesenteric blood vessels." Thrombin may be a potent stimulator of PG synthesis in many tissues since it is known that thrombin stimulates PG synthesis by platelets" and recently a similar action was demonstrated in fibroblasts maintained in tissue culture.
1 * This action of thrombin may be specific since 0.9% saline, hypertonic saline, or air embolism does not elicit a similar action in our experiments.
It is unlikely that the elevation of PG's was due to their presence in the thrombin preparation since these should be removed during purification. Moreover, preliminary experiments show that exogenous PG's rapidly disappear from the site of intrathecal injection, having a half time of approximately 8 minutes. Therefore, the elevated levels observed 2 hours after the injection of thrombin is most likely due to endogenous synthesis.
Whether these experimental findings are applicable to what is seen in patients with subarachnoid hemorrhage is problematic. It has been reported 19 ' 20 that 1 ml of blood generates 300-360 units of thrombin so 3 ml of blood released during hemorrhage could generate approximately as much thrombin as used in these studies, 1,000 U. Experimentally, 2 ml of blood or as little as 100 units thrombin injected intrathecally are capable of eliciting spasm.' Thus, it seems reasonable that a similar process could occur in patients as demonstrated in these experiments. The inflammation and cerebral vasospasm which occurs in patients following subarachnoid hemorrhage could be explained, in part at least, by the release of thrombin and subsequent production of PG's.
In spite of the mechanism(s) involved, the results suggest that the use of thrombin during intracerebral surgery should be done with caution.
